Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an update.
Radiopharm Theranostics Limited has reported a change in the substantial holding interests by JPMorgan Chase & Co. and its affiliates, indicating a decrease in voting power from 8.54% to 7.48%. This change reflects transactions involving securities lending and proprietary trading by J.P. Morgan entities. The adjustment in holdings may influence Radiopharm Theranostics’ shareholder dynamics and could impact the company’s strategic decisions moving forward.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates within the medical industry, focusing on the development of radiopharmaceuticals for diagnostic and therapeutic purposes. The company aims to leverage advanced imaging technologies to improve the detection and treatment of various diseases, targeting a global market with its innovative solutions.
YTD Price Performance: 30.0%
Average Trading Volume: 9,669,060
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$60.68M
See more insights into RAD stock on TipRanks’ Stock Analysis page.